These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 23782127)

  • 1. Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study.
    Wake R; Miyaoka T; Inagaki T; Furuya M; Ieda M; Liaury K; Kishi K; Horiguchi J
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):329-36. PubMed ID: 23782127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study.
    Miyaoka T; Wake R; Furuya M; Liaury K; Ieda M; Kawakami K; Tsuchie K; Inagaki T; Horiguchi J
    BMC Psychiatry; 2012 Nov; 12():215. PubMed ID: 23194148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Yokukansan, a Japanese Kampo Medicine for Symptoms Associated Autism Spectrum Disorder.
    Wake R; Miyaoka T; Furuya M; Hashioka S; Horiguchi J
    CNS Neurol Disord Drug Targets; 2016; 15(5):551-63. PubMed ID: 27071791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.
    Stigler KA; Diener JT; Kohn AE; Li L; Erickson CA; Posey DJ; McDougle CJ
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):265-74. PubMed ID: 19519261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.
    Posey DJ; Guenin KD; Kohn AE; Swiezy NB; McDougle CJ
    J Child Adolesc Psychopharmacol; 2001; 11(3):267-77. PubMed ID: 11642476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.
    Posey DJ; Wiegand RE; Wilkerson J; Maynard M; Stigler KA; McDougle CJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):599-610. PubMed ID: 17069548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paliperidone for irritability in adolescents and young adults with autistic disorder.
    Stigler KA; Mullett JE; Erickson CA; Posey DJ; McDougle CJ
    Psychopharmacology (Berl); 2012 Sep; 223(2):237-45. PubMed ID: 22549762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
    Shea S; Turgay A; Carroll A; Schulz M; Orlik H; Smith I; Dunbar F
    Pediatrics; 2004 Nov; 114(5):e634-41. PubMed ID: 15492353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study.
    Marcus RN; Owen R; Manos G; Mankoski R; Kamen L; McQuade RD; Carson WH; Corey-Lisle PK; Aman MG
    J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):229-36. PubMed ID: 21663425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study.
    Masi G; Cosenza A; Millepiedi S; Muratori F; Pari C; Salvadori F
    CNS Drugs; 2009; 23(6):511-21. PubMed ID: 19480469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder.
    Owen R; Sikich L; Marcus RN; Corey-Lisle P; Manos G; McQuade RD; Carson WH; Findling RL
    Pediatrics; 2009 Dec; 124(6):1533-40. PubMed ID: 19948625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy of irritability in pervasive developmental disorders.
    Stigler KA; McDougle CJ
    Child Adolesc Psychiatr Clin N Am; 2008 Oct; 17(4):739-52, vii-viii. PubMed ID: 18775367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective open trial of guanfacine in children with pervasive developmental disorders.
    Scahill L; Aman MG; McDougle CJ; McCracken JT; Tierney E; Dziura J; Arnold LE; Posey D; Young C; Shah B; Ghuman J; Ritz L; Vitiello B
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):589-98. PubMed ID: 17069547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders.
    Hollander E; Chaplin W; Soorya L; Wasserman S; Novotny S; Rusoff J; Feirsen N; Pepa L; Anagnostou E
    Neuropsychopharmacology; 2010 Mar; 35(4):990-8. PubMed ID: 20010551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.
    Potenza MN; Holmes JP; Kanes SJ; McDougle CJ
    J Clin Psychopharmacol; 1999 Feb; 19(1):37-44. PubMed ID: 9934941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study of memantine in children and adolescents with pervasive developmental disorders.
    Erickson CA; Posey DJ; Stigler KA; Mullett J; Katschke AR; McDougle CJ
    Psychopharmacology (Berl); 2007 Mar; 191(1):141-7. PubMed ID: 17016714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder.
    Marcus RN; Owen R; Kamen L; Manos G; McQuade RD; Carson WH; Aman MG
    J Am Acad Child Adolesc Psychiatry; 2009 Nov; 48(11):1110-1119. PubMed ID: 19797985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder.
    Aman MG; Kasper W; Manos G; Mathew S; Marcus R; Owen R; Mankoski R
    J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):415-22. PubMed ID: 20973712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders.
    Owley T; Salt J; Guter S; Grieve A; Walton L; Ayuyao N; Leventhal BL; Cook EH
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):517-24. PubMed ID: 17069541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.